BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced it entered into an agreement with Ovation Pharmaceuticals, Inc. for the supply of the active ingredient used in the production of Enzon’s Oncaspar®. Oncaspar is a form of L-asparaginase enhanced with Enzon’s PEGylation technology for the treatment of Acute Lymphoblastic Leukemia or ALL. The existing supply agreement with Ovation expired on December 31, 2006. Under the new agreement, Ovation has agreed to supply a sufficient quantity of L-asparaginase material through 2009.
